Medicare CED Decisions By Local Contractors Would Be Unworkable, Drug Firms Argue
Executive Summary
In comments to the Centers for Medicare and Medicaid Services, drug manufacturers also say CED should continue to be applied only “rarely” for drugs and biologics and should not apply to off-label uses.
You may also be interested in...
CMS Sets The Stage For New Medicare "Coverage With Evidence Development" Guidance
A rarely-used tool for gathering data on medical technologies will get a fresh look as the agency solicits public comment on how to make CED a more meaningful and effective part of its coverage decision-making process.
Insurer Seeks To Recover ‘Illegal’ Daraprim Overcharges Due To Obstruction Of Generics
Proposed class action lawsuit by Blue Cross Blue Shield of Minnesota against Vyera Pharmaceuticals could set a precedent for other health insurer actions against manufacturers.
Tie Goes To The Nominee: Becerra Heads To Senate Floor
Without Republican support, Biden’s HHS nominee couldn’t get a majority in the Finance Committee, but that shouldn’t imperil his bid to become secretary of Health and Human Services.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: